• PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED
• This FDA-aligned trial targets the specific TNFR1 genotype to maximize treatment effects, with ~70% of clinical sites already activated and patients in the run-in phase
• With only 13% of DED patients experiencing sustained relief, Licaminlimab has the potential to offer a targeted precision solution for a highly unsatisfied market

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.